Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hentig

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Antimicrobial Agents and Chemotherapy|April 16, 2008
Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimenNils von Hentig, Pavel Kaykhin, Christoph Stephan, et al.
Transfusion|October 1, 2009
Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective studyInmaculada Martinez-Saguer, Eva Rusicke, Emel Aygören-Pürsün, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|May 22, 2010
Higher pain scores, similar opioid doses and side effects associated with antipyretic analgesics in specialised tertiary pain careJörn Lötsch, Rainer Freynhagen, Nils von Hentig, et al.
Journal of Clinical Pharmacology|September 18, 2007
Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activityJochen Graff, Nils von Hentig, Frank Misselwitz, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2007
Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1Jörn Lötsch, Sebastian Harder, Martin Stürmer, et al.
European Journal of Medical Research|November 15, 2006
Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelinesNils von Hentig, C Koenigs, S Elanjikal, et al.
The Journal of Antimicrobial Chemotherapy|December 25, 2007
Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivoJochen Graff, Nils von Hentig, Karina Kuczka, et al.
Pharmacogenetics and Genomics|April 18, 2009
Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitutionAlexandra Doehring, Nils von Hentig, Jochen Graff, et al.
The Clinical Journal of Pain|October 24, 2009
Cross-sectional assessment of the consequences of a GTP cyclohydrolase 1 haplotype for specialized tertiary outpatient pain careAlexandra Doehring, Rainer Freynhagen, Norbert Griessinger, et al.
The Journal of Antimicrobial Chemotherapy|May 15, 2008
The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factorsNils von Hentig, Errol Babacan, Tessa Lennemann, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|April 16, 2008
Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimenNils von Hentig, Pavel Kaykhin, Christoph Stephan, et al.
Transfusion|October 1, 2009
Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective studyInmaculada Martinez-Saguer, Eva Rusicke, Emel Aygören-Pürsün, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|May 22, 2010
Higher pain scores, similar opioid doses and side effects associated with antipyretic analgesics in specialised tertiary pain careJörn Lötsch, Rainer Freynhagen, Nils von Hentig, et al.
Journal of Clinical Pharmacology|September 18, 2007
Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activityJochen Graff, Nils von Hentig, Frank Misselwitz, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2007
Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1Jörn Lötsch, Sebastian Harder, Martin Stürmer, et al.
European Journal of Medical Research|November 15, 2006
Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelinesNils von Hentig, C Koenigs, S Elanjikal, et al.
The Journal of Antimicrobial Chemotherapy|December 25, 2007
Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivoJochen Graff, Nils von Hentig, Karina Kuczka, et al.
Pharmacogenetics and Genomics|April 18, 2009
Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitutionAlexandra Doehring, Nils von Hentig, Jochen Graff, et al.
The Clinical Journal of Pain|October 24, 2009
Cross-sectional assessment of the consequences of a GTP cyclohydrolase 1 haplotype for specialized tertiary outpatient pain careAlexandra Doehring, Rainer Freynhagen, Norbert Griessinger, et al.
The Journal of Antimicrobial Chemotherapy|May 15, 2008
The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factorsNils von Hentig, Errol Babacan, Tessa Lennemann, et al.
Pageof 6